A new lawsuit against Nova Kratom highlights a critical gap in supplement regulation: products marketed as harmless herbal remedies may carry serious health risks that consumers never see coming. Alejandro Mendoza filed suit in Nevada District Court on July 20, alleging he developed severe addiction, cardiac injuries, and withdrawal symptoms after using Nova Kratom products that were marketed as safe and natural. The case was moved to federal court on August 6, raising questions about how dietary supplements can be sold without FDA approval or adequate safety warnings.

What Is Kratom and Why Is It Unregulated?

Kratom is a psychoactive substance derived from the leaves of the Mitragyna tree, native to Southeast Asia. It is widely available in the United States in multiple forms, including powders, capsules, tablets, extracts, concentrated shots, gummies, and beverages, sold at gas stations, smoke shops, convenience stores, wellness stores, and online. Despite its popularity, the U.S. Food and Drug Administration (FDA) has never approved kratom for any use, leaving it in a regulatory gray zone where companies can market it with minimal oversight.

The substance is known to interact with some of the same brain receptors targeted by opioids such as morphine and heroin, yet it continues to be sold as a dietary supplement rather than a controlled substance. This legal distinction matters enormously: dietary supplements face far fewer pre-market safety requirements than drugs, allowing products to reach consumers before their risks are fully understood.

How Has Kratom Use Affected Public Health?

The health impact of kratom has grown dramatically in recent years. A report published by the U.S. Centers for Disease Control and Prevention (CDC) indicates kratom poisoning cases have increased by more than 1,200% since 2015. This explosive rise coincides with increasingly potent kratom products being sold without FDA approval or oversight, raising concerns that manufacturers are making stronger formulations to compete in an unregulated market.

According to the lawsuit, kratom use can trigger a range of serious health consequences. Mendoza's complaint identifies the following risks associated with kratom consumption:

• Addiction and Dependence: Kratom products are highly addictive and possess opioid-like properties that can lead to physical and psychological dependence, similar to prescription opioids.
• Withdrawal Symptoms: Users who stop taking kratom may experience agitation, irritability, insomnia, anxiety, tremors, body aches, nausea, and vomiting.
• Serious Organ and Cardiac Damage: Potential health risks include seizures, organ damage, cardiac problems, respiratory depression, coma, and death.

The lawsuit alleges that MIB Inc., doing business as Nova Kratom, marketed its products as "all natural" herbal supplements without adequately testing them or warning consumers about addiction, withdrawal, and other health risks. Mendoza claims he would not have purchased the products if proper warnings had been provided.

Who Is Being Targeted by Kratom Marketing?

The lawsuit raises another troubling concern: kratom companies may be deliberately targeting vulnerable populations. Mendoza alleges that kratom is marketed toward young and vulnerable consumers, including individuals struggling with or recovering from addiction, as a way to boost energy, improve mood, relieve pain, and ease opioid withdrawal. By positioning kratom as a natural alternative for people seeking to manage addiction or pain, companies like MIB may be exploiting consumers' vulnerability to an addictive substance to develop repeat customers through dependence.

This marketing strategy is particularly concerning given that many people turn to kratom specifically because they are trying to avoid prescription opioids or manage withdrawal symptoms. Instead of finding relief, they may be trading one addiction for another.

What Legal Claims Are Being Made Against Nova Kratom?

Mendoza's complaint raises multiple legal allegations against MIB Inc., reflecting the scope of the company's alleged misconduct. The lawsuit includes claims of strict products liability for design defect and unreasonably dangerous products, failure to warn consumers, negligence, breach of implied warranties of merchantability and fitness for a particular purpose, breach of express warranty, and deceptive trade practices or consumer fraud.

The complaint states: "Defendants' kratom products were defective and unreasonably dangerous because Defendants failed to provide any adequate warning of the products' addictive, opioid-like properties, the symptoms of withdrawal from their use, and the serious and potentially fatal health consequences of their use, dangers of which Defendants knew or, in the exercise of reasonable care, should have known".

Mendoza is seeking compensation for past and future medical expenses, pain and suffering, mental anguish, loss of enjoyment of life, diminished earning capacity, and lost wages. The case is part of a growing wave of kratom lawsuits filed in federal courts alleging that products made from the substance are highly addictive and pose significant dangers to users.

Why Does the FDA Struggle to Regulate Supplements?

The kratom lawsuit underscores a fundamental weakness in how the United States regulates dietary supplements. Unlike pharmaceutical drugs, which must be proven safe and effective before reaching the market, dietary supplements can be sold with minimal pre-market review. The FDA can only take action after a product is already on shelves and has caused documented harm. This reactive approach means consumers often serve as unwitting test subjects for unproven products.

Kratom's legal status as a dietary supplement rather than a drug is the key reason it has proliferated despite growing evidence of serious health risks. As long as companies avoid making explicit medical claims on their labels, they can market kratom with vague wellness language like "natural energy support" or "mood enhancement," leaving consumers unaware of the addiction and cardiac risks documented in medical literature and now alleged in court.

The 1,200% increase in kratom poisoning cases since 2015 suggests that the current regulatory framework is failing to protect public health. Until the FDA takes stronger action or Congress changes supplement regulations, consumers will continue to face products that prioritize profit over safety.

" }